Syndax Pharmaceuticals has partnered with Roche Group member Genentech to begin a Phase Ib/II clinical trial of entinostat in combination with atezolizumab (Tecentriq) to treat the second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic type of breast cancer.

The open-label, multicentre, randomised trial seeks to evaluate the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer.

The study aims to enrol patients with metastatic HR+, HER2- breast cancer who have experienced disease progression during or following first-line therapy.

It will be carried out by Genentech under Roche’s new cancer immunotherapy development platform MORPHEUS, which is a Phase Ib/II adaptive platform to develop combinations of cancer immunotherapies rapidly.

“While checkpoint inhibitors have shown initial promise in triple-negative breast cancer, there is a clear need to augment the effectiveness of such therapies in the setting of HR+, HER2- breast cancer.”

Syndax Pharmaceuticals CEO Briggs Morrison said: “This collaboration represents further validation of the ongoing interest to test the potential ability of Syndax’s entinostat to enhance the effectiveness of an immuno-oncology therapy in an area of unmet medical need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“While checkpoint inhibitors have shown initial promise in triple-negative breast cancer, there is a clear need to augment the effectiveness of such therapies in the setting of HR+, HER2- breast cancer.”

Syndax added that its entinostat is an oral, small molecule, class I HDAC inhibitor, while Genentech’s atezolizumab (TECENTRIQ) is a programmed cell death ligand 1 (PD-L1) blocking antibody.

In 2015, Syndax partnered with Genentech to conduct a Phase Ib/II trial to examine the safety, tolerability and clinical activity of entinostat in combination with TECENTRIQ in triple-negative breast cancer.

The ENCORE 602 trial is expected to complete patient enrolment forits Phase II portion in the first half of this year.